Evidence map›Paper›PMID 39714464›Full record

ArticleeLife2024

Base editing of

Desiree Böck, Maria Wilhelm, Jonas Mumenthaler, Daniel Fabio Carpanese, Peter I Kulcsár, Simon d'Aquin, Alessio Cremonesi, Anahita Rassi, Johannes Häberle, Tommaso Patriarchi and 1 more

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. CRISPR-Based Gene Therapy for Brain Disease.Molecular neurobiology · 2026
    Review
  3. RNArchitects: how hnRNPs shape neuronal landscapes.Brain : a journal of neurology · 2026
    Review
  4. Article
  5. Prime editing of the βNature communications · 2025
    Article
  6. Article
  7. Molecular therapy. Nucleic acids · 2025
    Review
  8. Article
  9. Base editing ofeLife · 2024
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Desiree Böck *Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-8142-0629
Maria Wilhelm *Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Jonas MumenthalerInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Daniel Fabio CarpaneseInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Peter I KulcsárInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Simon d'AquinInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Alessio CremonesiDivision of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Anahita RassiDivision of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Johannes HäberleDivision of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Tommaso PatriarchiInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-9351-3734
Gerald SchwankInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-0767-2953

Funding

European Research Council 891959Novartis Foundation for Medical-Biological Research FN20-0000000203Swiss National Science Foundation 196287Swiss National Science Foundation 310030_185293Swiss National Science Foundation 310030_196455
6 · The paper itself

Abstract

Parkinson's disease (PD) is a multifactorial disease caused by irreversible progressive loss of dopaminergic neurons (DANs). Recent studies have reported the successful conversion of astrocytes into DANs by repressing polypyrimidine tract binding protein 1 (PTBP1), which led to the rescue of motor symptoms in a chemically-induced mouse model of PD. However, follow-up studies have questioned the validity of this astrocyte-to-DAN conversion model. Here, we devised an adenine base editing strategy to downregulate PTBP1 in astrocytes and neurons in a chemically-induced PD mouse model. While PTBP1 downregulation in astrocytes had no effect, PTBP1 downregulation in neurons of the striatum resulted in the expression of the DAN marker tyrosine hydroxylase (TH) in non-dividing neurons, which was associated with an increase in striatal dopamine concentrations and a rescue of forelimb akinesia and spontaneous rotations. Phenotypic analysis using multiplexed iterative immunofluorescence imaging further revealed that most of these TH-positive cells co-expressed the dopaminergic marker DAT and the pan-neuronal marker NEUN, with the majority of these triple-positive cells being classified as mature GABAergic neurons. Additional research is needed to fully elucidate the molecular mechanisms underlying the expression of the observed markers and understand how the formation of these cells contributes to the rescue of spontaneous motor behaviors. Nevertheless, our findings support a model where downregulation of neuronal, but not astrocytic, PTBP1 can mitigate symptoms in PD mice.

Indexed as

AstrocytesDisease Models, AnimalHeterogeneous-Nuclear RibonucleoproteinsParkinson DiseasePolypyrimidine Tract-Binding ProteinAnimalsCorpus StriatumDopaminergic NeuronsGene EditingMaleMiceMice, Inbred C57BLTyrosine 3-MonooxygenaseHeterogeneous-Nuclear RibonucleoproteinsPolypyrimidine Tract-Binding ProteinPtbp1 protein, mouseTyrosine 3-Monooxygenase6-OHDAbase editingCRISPR-casgene therapymouseneuroscienceparkinson's diseasePtbp1regenerative medicinestem cells

Identifiers

PMID39714464
PMCPMC11666242

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.